Research programme: adnectin-based therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: adnectin-based therapeutics - Bristol-Myers Squibb

Alternative Names: Bispecific Adnectin™ inhibitor; Bispecific EGFR-IGFR Adnectins™; EGFR/IGFR tandem adnectin; EI-tandem; FGF21-PKE Adnectin™; IL-23 Adnectin inhibitor™; IL-23 Adnectin™

Latest Information Update: 08 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adnexus Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Proteins
  • Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor 21 agonists; Insulin-like growth factor-I receptor antagonists; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Immunological disorders
  • Discontinued Metabolic disorders

Most Recent Events

  • 08 Sep 2015 Preclinical development is underway in USA
  • 07 Nov 2013 Preclinical development is ongoing for Immunological disorders and Cancer in USA
  • 07 Nov 2013 Discontinued - Preclinical for Metabolic disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top